TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

This study is testing a new oral drug called TGRX-678 for people with chronic myelogenous leukemia (CML) — a type of blood cancer — that has not responded to or cannot be tolerated with existing targeted treatments (called TKIs, or tyrosine kinase inhibitors). The study aims to find the right dose and assess safety. **You may be eligible if...** - You are 18 or older - You have been diagnosed with CML in the chronic phase - Your cancer has become resistant to or you cannot tolerate TKI treatments - Your organ function (kidneys, liver, bone marrow) is within acceptable limits - Your heart rhythm (QT interval) is normal on an ECG - If female, you must have a negative pregnancy test and use effective contraception **You may NOT be eligible if...** - You are currently receiving or recently received another anti-cancer therapy - You are in the accelerated or blast phase of CML - You have serious heart rhythm problems - You are pregnant or breastfeeding - You have participated in another clinical trial recently Talk to your doctor to see if this trial is right for you.